1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Belharra Therapeutics Collaborates with Sanofi to Advance Discovery of Novel Therapeutics

21 Jun 2024
Admin
News Article

Belharra Therapeutics Collaborates with Sanofi to Advance Discovery of Novel Therapeutics

Belharra Therapeutics collaborates with Sanofi to advance discovery of novel therapeutics for immunological diseases

Overview

Belharra Therapeutics, a next-generation chemoproteomics company transforming small molecule drug discovery by illuminating binding pockets on elusive, high-value drug targets across the proteome, announced a strategic collaboration with Sanofi to advance the discovery of novel small molecule therapeutics for immunological diseases.

Post Collaboration

The collaboration will leverage Belharra’s proprietary non-covalent chemoproteomics platform to screen and validate hits against undisclosed Sanofi-designated immunology targets.
Belharra is eligible to receive up to $40 million in upfront and near-term milestone payments, with a potential total deal value of up to nearly $700 million in payments over the course of the collaboration in research, development and commercial milestones, as well as tiered royalties on net sales.

Words from CEO: Belharra

“We look forward to combining the powerful capabilities of Belharra’s next-generation chemotherapeutics platform with Sanofi’s vast expertise in immunology research and development as we work together toward discovering new therapeutics for challenging-to-treat diseases,” said Jeff Jonker, CEO of Belharra.
“With the ability to illuminate any pocket, on any protein, in any cell type, our platform enables perhaps the broadest and most unbiased chemoproteomic screening capabilities in the industry.”
“Leveraging the platform, we have built a robust internal pipeline focused on oncology and immunology and are thrilled to simultaneously engage with therapeutic area leaders like Sanofi to maximize the platform’s potential to discover a wave of new first-in-class and best-in-class drugs for unmet patient needs.”

Words from Sanofi

“Our collaboration with Belharra demonstrates our efforts to build on our achievements in delivering first-in-class treatments for chronic inflammatory diseases by pushing the science of immunology further to advance new therapeutics that could change patients’ lives,” said John Bertin, global head of immunology and inflammation research, Sanofi.
“By leveraging Belharra’s chemoproteomics platform, we hope to explore immunology targets that, to date, have been considered undruggable.”

Belharra

Belharra’s platform is designed to enable the industry’s broadest and most unbiased chemoproteomic screening capabilities.
The platform leverages a computationally designed library of non-covalent drug-like molecules that use photoaffinity chemistry to identify which proteins bind the molecules as well as the precise binding location on the target proteins.
All screens are conducted in a native cellular environment.
Using this approach, Belharra is able to illuminate any binding pocket on any protein or protein-protein interaction, in any cell type, yielding insights that enable the discovery of new drugs for well-validated but elusive protein targets as well as novel drug targets.
Belharra Therapeutics’ proprietary screening platform has the potential to yield a new wave of first-in-class or best-in-class therapeutics to address a broad spectrum of challenging and, to date, intractable diseases.